Updates from Syncona and our portfolio companies
A pan-checkpoint inhibition strategy programmed into CAR T-cells.
Autolus Limited, a clinical-stage biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies, today announced the publication of an article in Nature Medicine describing a unique targeting strategy for the treatment of patients with T-cell lymphomas.
Nightstar Therapeutics plc (NASDAQ: NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that the company will participate in the following industry and investor conferences in November.
Blue Earth Diagnostics, a molecular imaging diagnostics company, and Seibersdorf Laboratories, a leading developer and manufacturer of radiopharmaceuticals, today announced that they have entered into an exclusive distribution agreement and a non-exclusive manufacturing agreement for the supply of Blue Earth Diagnostics’ Positron Emission Tomography (PET) imaging product Axumin® (fluciclovine (18F)) in certain European countries.
Agreement marks first step towards full commercial availability of Axumin® (fluciclovine( 18F)) in the UK.
Results presented at 2017 ASTRO Annual Meeting evaluate clinical utility of fluciclovine (18F) PET/CT imaging in men with recurrent prostate cancer following prior treatment.
Gyroscope Therapeutics, an ophthalmology company developing genetically defined therapies for retinal diseases such as age related macular degeneration (AMD), is pleased to announce the appointment of Dr Soraya Bekkali as Chief Executive Officer and Director of its Board.
Blue Earth Diagnostics, a molecular imaging diagnostics company and M2i, a manufacturer of Positron Emission Tomography (PET) imaging agents, today announced that they have entered into an exclusive manufacturing and distribution agreement for the supply of Blue Earth Diagnostics’ PET imaging product Axumin™ (fluciclovine (18F)) in Ireland. M2i, through their Dublin PET manufacturing site, will bring Axumin to market in the Republic of Ireland and in Northern Ireland.
Autolus Limited, a biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies for haematological and solid tumors, announces a number of senior leadership appointments in preparation for development and commercialisation of its highly differentiated and innovative T-cell products.
Freeline Therapeutics (“Freeline”), a biopharmaceutical company focused on the development of curative gene therapies for bleeding and other debilitating disorders, today announced that Anne Prener has been appointed Chief Executive Officer.